ANTI-INFECTIVE COATING OF GENTAMICIN SULPHATE ENCAPSULATED PEG/PVA/CHITOSAN FOR PREVENTION OF BIOFILM FORMATION

  • Abdul Mannan Applied Mechanics Department, Motilal Nehru National Institute of Technology, Allahabad, UP, 211004, India
  • S. J. Pawar Applied Mechanics Department, Motilal Nehru National Institute of Technology, Allahabad, UP, 211004, India

Abstract

Objective: The main aim of the current study is to show Anti-infective coating on biomedical implants, one of the novel approaches to control the biofilm formation.

Methods: In this study, the coating was employed by the slurry of Polyvinyl alcohol (PVA),Polyethylene glycol (PEG) and Chitosan with encapsulated Gentamicin Sulphate (GS) using Slurry-dipping technique on Silicon. Two different strategies were followed to coat the Silicone namely Coating I with chitosan and Coating II without chitosan. Drug encapsulation efficiencies of Coating I and Coating II were found to be 86.8% and 83.96% respectively.

Results: In vitro drug release profile of Coating I and Coating II in phosphate buffer saline at pH 7.4 for 48 hrs were found to be 30.3µg/ml and 24.2 µg/ml respectively. Antimicrobial activity of coated samples against Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli showed effective results. Biofilm formation was investigated by XTT reduction assay which showed reduction of biofilm on coated sample with respect to the uncoated sample. Biocompatibility of coated sample was confirmed by MTT assay against SW-71 trophoblast cell-lines and hemolysis test against fresh human blood. Surface morphological analysis using SEM confirmed the uniform coating and AFM showed the average surface roughness reduction in coated sample.

Conclusion: The present study indicated that GS encapsulated PVA, PEG and Chitosan cross linked polymer coated Silicone can be potentially used for production of Silicone based implant.

 

Keywords: Biofilm, Biomedical implant, Silicone, Biocompatibility, Cytotoxicity, Drug encapsulation, Hemocompatibility.

Downloads

Download data is not yet available.

References

1. Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis 2002;8(9):881-90.
2. Joung Y. Development of implantable medical devices: from an engineering perspective. Int Neurourol J 2013;17(3):98–106.
3. Shapiro IM, Hickok NJ, Parvizi J, Stewart S, Schaer TP. Molecular engineering of an orthopaedic implant: from bench to bedside. Eur Cells Materials 2012;23:362-70.
4. Dunne WM. Bacterial adhesion: seen any good biofilms lately? Clin Microbiol Rev 2002;15(2):155–66.
5. Khardori N, Yassien M. Biofilms in device-related infections. J Ind Microbiol 1995;15:141–7.
6. Von Eiff C, Heilmann C, Peters, G. New aspects in the molecular basis of polymer-associated infections due to staphylococci. Eur J Clin Microbiol Infect Dis 1999;18(12):843-6.
7. Bengtson S, Knutson K. The infected knee arthroplasty. A 6-year follow-up of 357 cases. Acta Orthop Scand 1991;62(4):301-11.
8. Barton AJ, Sagers RD, Pitt WG. Bacterial adhesion to orthopedic implant polymers. J Biomed Mater Res 1996;30:403-10.
9. Tattevin P, Cremieux AC, Pottier P, Huten D, Carbon C. Prosthetic joint infection: when can prosthesis salvage be considered? Clin Infect Dis 1999;29(2):292-5.
10. Chen M, Yu Q, Sun H. Novelstrategies for the prevention and treatment of biofilm related infections. Int J Mol Sci 2013;14(9):18488–501.
11. Boccaccini AR, Stamboulis AG, Rashid A, Roether JA. Composite surgical sutures with bioactive glass coating. J Biomed Mater Res B Appl Biomater 2003;67:618–26.
12. Stamboulis AG, Boccaccini AR, Hench LL. Novel biodegradable polymer/bioactive glass composites for tissue engineering applications. Adv Eng Mater 2002;4:105–9.
13. Moffat A. Clark’s Isolation and Identification of Drugs. 2nd edn. London: The Pharmaceutical Press; 1989.
14. Frutos P, Torrado S, Perez-Lorenzo ME, Frutos G. A validated quantitative colorimetric assay for gentamicin. J Pharm Biomed Anal 2000;21(6):1149-59.
15. Stevens MG, Olsen SC. Comparative analysis of using MTT and XTT in colorimetric assays for quantitating bovine neutrophil bactericidal activity. J Immunol Methods 1993;157:225-31.
16. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 1991;142:257-65.
17. Jin Y, Yip HK, Samaranayake YH, Yau JY, Samaranayake LP. Biofilm-forming ability of candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. J Clin Microbiol 2003;41(7):2961-7.
18. ASTM. Standard practice for assessment of hemolytic properties of materials. 2009:F756-08.
19. ASTM; F619 − Standard Practice for Extraction of Medical Plastics. 2008;03.
20. Horcas I, Fernandez R, Gomez-Rodriguez JM, Colchero J, Gomez-Herrero J. WSXM: A software for scanning probe microscopy and a tool for nanotechnology. Rev Sci Instrum 2007;78:013705-8.
Statistics
315 Views | 1413 Downloads
How to Cite
Mannan, A., and S. J. Pawar. “ANTI-INFECTIVE COATING OF GENTAMICIN SULPHATE ENCAPSULATED PEG/PVA/CHITOSAN FOR PREVENTION OF BIOFILM FORMATION”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 6, no. 10, 1, pp. 571-6, https://innovareacademics.in/journals/index.php/ijpps/article/view/1213.
Section
Original Article(s)